I see nothing here that compared this to other fast diagnosis possibilities. So further research is once again required which will never occur, you will continue to be screwed until we get a
great stroke association. Notice time of seconds to diagnose and no neurologist needed.
http://www.prnewswire.com/news-releases/novel-device-shows-promise-for-early-identification-of-serious-strokes-300494693.html
Results of the VITAL study presented as a Late Breaker at the 14th
Annual Meeting of The Society of NeuroInterventional Surgery demonstrate
how a new technology may change the paradigm of emergency stroke care.
PLEASANTON, Calif.,
July 26, 2017 /PRNewswire/ --
Cerebrotech Medical Systems,
an innovative medical device company focused on the development of
portable neurotechnology solutions, today reported results from a new
study evaluating its proprietary VIPS™ technology for emergency stroke
patients. The results of the study, VITAL, which are being presented at
the 14th Annual Meeting of
The Society of NeuroInterventional Surgery in
Colorado Springs, CO,
demonstrate that Cerebrotech's non-invasive, visor-like neurological
device can identify those patients with large vessel occlusion (LVO)
strokes and large hemorrhagic strokes versus those with less urgent
strokes, allowing for earlier intervention to prevent further brain
damage.
"This multi-center clinical trial shows the viability
of a non-invasive technology that can quickly identify treatable
devastating strokes in ambulances or emergency rooms to enable rapid
triage those patients to specialized, capable treatment centers, thereby
saving lives," said
Christopher P. Kellner, M.D., Director of the Intracerebral Hemorrhage Program at
Mount Sinai and Assistant Professor of Neurosurgery at the Icahn School of Medicine at
Mount Sinai. "This trial demonstrates that Cerebrotech's device has the potential to do for stroke what EKG has done for heart attack."
Dr. Kellner presented data
demonstrating that Cerebrotech's device is capable of differentiating
large strokes from small strokes with sensitivity of 93% (95% CI 83-98)
and specificity of 92% (95% CI 75-99). Comparison of large strokes to
healthy adults yielded 100% specificity. Importantly, Kellner's
presentation also demonstrated the underlying reasons why the device
offers this level of accuracy. The data show that subjects with large
strokes (55 ischemic and 2 hemorrhagic) have significantly higher
bioimpedance asymmetry, a measure of the electrical characteristics of
the brain, compared to those with small strokes (16 ischemic and 10
hemorrhagic) that do not require emergent triage to special centers.
Large stroke subjects had an average asymmetry score of 16.5% (95% CI
14.6-18.4), versus those with small strokes, which had an average
asymmetry score of 8.0% (95% CI 6.9-9.0, p<0.0001). Average
bioimpedance asymmetry in a cohort of 79 healthy adults was 5.0% (95% CI
4.5-5.5). By measuring bioimpedance asymmetry, the device is able to
identify stroke and differentiate large strokes from small strokes.
The presented data
consisted of: the VITAL study (N=128), which evaluated patients
presenting with a range of brain injuries including strokes and was
conducted by a group that included distinguished researchers from Icahn
School of Medicine at
Mount Sinai (
New York City), The
Medical University of South Carolina, Jacobs School of Medicine and Biomedical Sciences at the
University at Buffalo, and Baptist Medical Center Jacksonville; an initial pilot study (N=41) conducted at The
Medical University of South Carolina; and a study of healthy volunteers for baseline comparators. The data were managed by
Vastrax, a first-of-its kind neurovascular clinical research and development partner.
"There is a critical,
highly-visible unmet need for effective, early stroke assessment in
ambulances and emergency rooms to identify which patients need triage
directly to specialty stroke hospitals for immediate surgical
intervention," said
Mitch Levinson,
President and CEO, Cerebrotech Medical Systems. "By helping to minimize
treatment delays, this technology has the potential to substantially
improve healthcare outcomes for hundreds of thousands of people each
year across the globe."
Cerebrotech's technology,
Volumetric Integral Phase-shift Spectroscopy (VIPS), passes low-energy
electromagnetic waves through the brain, detecting small changes to the
brain's electrical properties. These electrical characteristics, called
bioimpedance, are related to brain tissue and fluid status, and
asymmetries can be indicative of clinical problems. Quantitative results
provided by the device can
be obtained in seconds by medical
professionals after
minimal training, and the simple device design
allows results to be obtained without interfering with any aspect of
patient care. The device holds a CE mark, but is not yet cleared for
sale in the U.S.
Early detection of brain
injury means early intervention, which can greatly improve patient
outcomes and transform the management paradigm of these life-threatening
neurological events. Every 45-minute reduction in time to thrombectomy,
the new standard of care for large vessel occlusion strokes, yields a
10% increase in the number of patients achieving functional independence
at 3 months.
1
The Society of
NeuroInterventional Surgery (SNIS), a worldwide scientific and
educational association, is dedicated to excellence in comprehensive,
minimally-invasive care of patients with stroke, brain aneurysms, and
other diseases in the head, neck and spine. SNIS draws its membership
from three areas - interventional neuroradiology, endovascular
neurosurgery and interventional neurology.
About Cerebrotech Medical SystemsCerebrotech Medical Systems,
Inc., is a venture capital-backed company dedicated to designing
neurotechnology solutions to improve the care of brain-injured patients
worldwide. The company is developing a portable, noninvasive
neuro-monitoring device that allows for earlier detection of potentially
life-threatening conditions such as large vessel occlusion stroke,
cerebral edema, traumatic brain injury, and others. Founded in 2010 and
based in
Pleasanton, CA, Cerebrotech's core intellectual property is licensed exclusively from the
University of California at Berkeley. For more information, visit
www.cerebrotechmedical.com.
1 Time to
Treatment With Endovascular Thrombectomy and Outcomes From Ischemic
Stroke: A Meta-analysis. JAMA. 2016;316(12):1279-1288.
doi:10.1001/jama.2016.13647